Licensing
Amarantus BioSciences Licenses Parkinson’s Biomarker Test
Amarantus BioSciences Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a disease–modifying therapeutic protein being developed for the treatment of Parkinson’s Disease, announced an exclusive worldwide license agreement with Power3 Medical Products Inc. for the NuroPro Blood Test as it relates to Parkinson’s disease diagnosis. The NuroPro Blood Test is Power3’s diagnostic platform for the early detection of neurodegenerative diseases. It is being developed as...
Lab21, Cooperative Diagnostics Reach License Agreement
Lab21 Ltd. announced the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed. Cooperative Diagnostics (Greenwood, SC) has undertaken innovative approaches to develop molecular technologies using biophysical models and statistical bioinformatics and has commercialized a series of assays in the infectious disease area...
HistoRx Licenses Assay from Yale
HistoRx licensed from Yale University a new clinical diagnostic assay based on AQUA technology. This assay enables doctors treating patients with melanoma to identify a subset of those patients who, despite having no detectable cancer in their lymph nodes, have a 40% risk of recurrence of their disease. AQUA technology is an automated, quantitative IHC testing method that enables measurement of protein biomarkers in tissue as an aid to a pathologist's diagnosis. Such precise determination of...
Genetic Technologies, AutoImmun Diagnostika Execute Settlement, License Agreement
In compliance with ASX Continuous Disclosure Rules, Genetic Technologies Ltd. has executed a Settlement and License Agreement with AutoImmun Diagnostika GmbH (AID) of Strassberg, Germany. Under the terms of the Agreement, AID is granted non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology. As with other similar agreements, the precise commercial terms of the Agreement are covered by formal confidentiality provisions and cannot be disclosed. AID was not...
QuantuMDx Receives Licenses from Nanosys for Advanced Materials
QuantuMDx Group Ltd. has signed an exclusive license agreement with Nanosys Inc. for several patents and patent applications related to the use of nanostructures for biosensors. The core intellectual property involves the use of nanowires and nanotubes in biosensors, including field effect transistors (FETs) biosensors, which were derived from the work of Prof. Charles Lieber, a professor of chemistry at Harvard and pioneer in nanotechnology. Under terms of the agreement, QuantuMDx has secured...
Accelr8, Schott Renew and Expand Microarray License
Accelr8 Technology Corp. and Schott Technical Glass Solutions GmbH have renewed Accelr8’s license to Schott for Nexterion microarraying slides using OptiChem biocoatings. In addition to renewing the existing non-exclusive license, Accelr8 also granted to Schott the right to sell OptiChem-coated products for application in medical diagnostics. Previously, Schott’s license excluded medical diagnostic applications. The new right for diagnostic products allows Schott to sell up to 20,...
Universal Biosensors, SpeeDx Reach License Agreement
Universal Biosensors Inc. (UBI) has signed a non-exclusive licence agreement with Australian company, SpeeDx Pty Ltd., for access to its proprietary MNAzyme technology. The SpeeDx technology is a sensitive and highly selective method for detecting sequences of DNA or RNA. The agreement allows UBI to utilize SpeeDx’s proprietary technology in combination with UBI's diagnostic biosensor to access the rapidly growing molecular diagnostics market. UBI will seek to develop a molecular...
TrovaGene Announces Licensing of Assay for Hairy Cell Leukemia
TrovaGene Inc. has signed a worldwide exclusive license for an assay that detects Hairy Cell Leukemia (HCL). A recent discovery, published in the June 16, 2011, New England Journal of Medicine by Dr. Brunangelo Falini and colleagues, showed that a specific mutation in the BRAF gene was present in all patients with HCL in the study. TrovaGene holds exclusive rights to the discovery and will offer nonexclusive licenses for its diagnostic application. The results of such a test will also help...
Allegro Diagnostics Enters License Agreement for Lung Cancer Molecular Testing Platform
Allegro Diagnostics has entered into an exclusive license agreement with Boston University and the University of Utah Foundation for intellectual property related to the company’s molecular testing platform. This platform utilizes gene expression of normal epithelial cells in the respiratory tract to detect early signs of lung cancer. Financial terms of the agreement are undisclosed. The field of injury principle on which the platform is based refers to the common molecular response that...
Exiqon Licenses Locked Nucleic Acids to Idexx Laboratories for Veterinary Diagnostics
Exiqon A/S has granted a non-exclusive license to Idexx Laboratories Inc. to use Exiqon’s proprietary LNA technology in defined products for veterinary disease diagnostics. Exiqon will receive upfront and milestones payments, and royalty on global sales of the products covered by this agreement. Financial terms of the agreement were not disclosed. “We are pleased to see Idexx Laboratories has chosen to apply Exiqon’s proprietary technology in the field of veterinary...